Paul Hahn1, Arseniy P Yashkin2, Frank A Sloan3. 1. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina. 2. Department of Economics, Duke University, Durham, North Carolina. 3. Department of Economics, Duke University, Durham, North Carolina. Electronic address: fsloan@duke.edu.
Abstract
PURPOSE: To investigate the effect of prior intravitreal anti-vascular endothelial growth factor (VEGF) injections on surgical and postoperative complication rates associated with cataract surgery in a nationally representative longitudinal sample of elderly persons. DESIGN: Retrospective, longitudinal cohort analysis. PARTICIPANTS: A total of 203 643 Medicare beneficiaries who underwent cataract surgery from January 1, 2009, to December 31, 2013. METHODS: By using the 5% sample of Medicare claims data, the study assessed risks of 3 adverse outcomes after receipt of cataract surgery for beneficiaries with a history of intravitreal injections. Risks of these outcomes in beneficiaries with a history of intravitreal injections relative to those without were calculated using the Cox proportional hazard model. MAIN OUTCOME MEASURES: The primary outcome was the risk of subsequent removal of retained lens fragments (RLFs) within 28 days after cataract surgery. Secondary outcomes were a new diagnosis of acute (<40 days) or delayed-onset (40+ days) endophthalmitis and risk of a new primary open-angle glaucoma (POAG) diagnosis within 365 days after cataract surgery. RESULTS: Prior intravitreal anti-VEGF injections were associated with a significantly increased risk of subsequent RLF removal within 28 days after cataract surgery (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.19-4.30). Prior injections were also associated with increased risk of both acute (HR, 2.29; 95% CI, 1.001-5.22) and delayed-onset endophthalmitis (HR, 3.65; 95% CI, 1.65-8.05). Prior injections were not a significant indicator of increased risk of a new POAG diagnosis. CONCLUSIONS: A history of intravitreal injections may be a risk factor for cataract surgery-related intraoperative complications and endophthalmitis. Given the frequency of intravitreal injections and cataract surgery, increased preoperative assessment, additional intraoperative caution, and postoperative vigilance are recommended in patients with a history of intravitreal injections undergoing cataract extraction.
PURPOSE: To investigate the effect of prior intravitreal anti-vascular endothelial growth factor (VEGF) injections on surgical and postoperative complication rates associated with cataract surgery in a nationally representative longitudinal sample of elderly persons. DESIGN: Retrospective, longitudinal cohort analysis. PARTICIPANTS: A total of 203 643 Medicare beneficiaries who underwent cataract surgery from January 1, 2009, to December 31, 2013. METHODS: By using the 5% sample of Medicare claims data, the study assessed risks of 3 adverse outcomes after receipt of cataract surgery for beneficiaries with a history of intravitreal injections. Risks of these outcomes in beneficiaries with a history of intravitreal injections relative to those without were calculated using the Cox proportional hazard model. MAIN OUTCOME MEASURES: The primary outcome was the risk of subsequent removal of retained lens fragments (RLFs) within 28 days after cataract surgery. Secondary outcomes were a new diagnosis of acute (<40 days) or delayed-onset (40+ days) endophthalmitis and risk of a new primary open-angle glaucoma (POAG) diagnosis within 365 days after cataract surgery. RESULTS: Prior intravitreal anti-VEGF injections were associated with a significantly increased risk of subsequent RLF removal within 28 days after cataract surgery (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.19-4.30). Prior injections were also associated with increased risk of both acute (HR, 2.29; 95% CI, 1.001-5.22) and delayed-onset endophthalmitis (HR, 3.65; 95% CI, 1.65-8.05). Prior injections were not a significant indicator of increased risk of a new POAG diagnosis. CONCLUSIONS: A history of intravitreal injections may be a risk factor for cataract surgery-related intraoperative complications and endophthalmitis. Given the frequency of intravitreal injections and cataract surgery, increased preoperative assessment, additional intraoperative caution, and postoperative vigilance are recommended in patients with a history of intravitreal injections undergoing cataract extraction.
Authors: Paul B Greenberg; Victoria L Tseng; Wen-Chih Wu; Jeffrey Liu; Lan Jiang; Christine K Chen; Ingrid U Scott; Peter D Friedmann Journal: Ophthalmology Date: 2010-10-29 Impact factor: 12.079
Authors: Robert J Campbell; Sherif R El-Defrawy; Sudeep S Gill; Marlo Whitehead; Erica de L P Campbell; Philip L Hooper; Chaim M Bell; Martin W Ten Hove Journal: JAMA Ophthalmol Date: 2019-01-01 Impact factor: 7.389
Authors: Ana Maria Cunha; Maria Manuel Iglésias; Amândio Rocha-Sousa; Fernando Falcão-Reis; Manuel Falcão Journal: J Ophthalmol Date: 2021-09-20 Impact factor: 1.909
Authors: Raul Velez-Montoya; Idaira Sanchez-Santos; Mauricio Galvan-Chavez; Lihteh Wu; J Fernando Arevalo; María H Berrocal; Arturo A Alezzandrini; Marta S Figueroa; Roberto Gallego-Pinazo; Rosa Dolz-Marco; Clara Martinez-Rubio; Roberto Gonzalez-Salinas Journal: J Ophthalmol Date: 2021-10-11 Impact factor: 1.909
Authors: Halah B Helayel; Ahmed A Alyahya; Adi M Al Owaifeer; Abdullah M Khan; Abdullah T Al Zahrani; Abdulrahman H Badawi; Rajiv Khandekar; Samar A Al-Swailem Journal: Saudi J Ophthalmol Date: 2022-08-29
Authors: Md Huzzatul Mursalin; Phillip S Coburn; Erin Livingston; Frederick C Miller; Roger Astley; Ana L Flores-Mireles; Michelle C Callegan Journal: Front Immunol Date: 2020-02-12 Impact factor: 7.561